Abstract
1 Many factors are of importance in the relationship between angina pectoris and hypertensive heart disease. Vascular resistance modifies the oxygen supply, whereas the oxygen demand is influenced by the systolic and diastolic BPs, the diastolic filling time and wall tension, the duration of systole and transmural pressure and the sympathetic stimulation to the heart.
2 The treatment of angina pectoris in patients with hypertensive heart disease should aim to reduce myocardial ischaemia, and it is suggested that β-adrenoceptor antagonists are most suitable, as they reduce BP, heart rate and myocardial contractility and thus oxygen demand.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Berglund G., Sannerstedt R., Andersson O., Wedel H., Wilhelmsen L., Hansson L., Sivertsson R., Wikstrand J. Coronary heart-disease after treatment of hypertension. Lancet. 1978 Jan 7;1(8054):1–5. doi: 10.1016/s0140-6736(78)90356-2. [DOI] [PubMed] [Google Scholar]
- Braunwald E. Thirteenth Bowditch lecture. The determinants of myocardial oxygen consumption. Physiologist. 1969 May;12(2):65–93. [PubMed] [Google Scholar]
- DAWBER T. R., KANNEL W. B. Susceptibility to coronary heart disease. Mod Concepts Cardiovasc Dis. 1961 Jul;30:671–676. [PubMed] [Google Scholar]
- Goodwin J. F., Oakley C. M. The cardiomyopathies. Br Heart J. 1972 Jun;34(6):545–552. doi: 10.1136/hrt.34.6.545. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gordon T., Kannel W. B. Premature mortality from coronary heart disease. The Framingham study. JAMA. 1971 Mar 8;215(10):1617–1625. [PubMed] [Google Scholar]
- Henry W. L., Clark C. E., Epstein S. E. Asymmetric septal hypertrophy (ASH): the unifying link in the IHSS disease spectrum. Observations regarding its pathogenesis, pathophysiology, and course. Circulation. 1973 Apr;47(4):827–832. doi: 10.1161/01.cir.47.4.827. [DOI] [PubMed] [Google Scholar]
- Hill L. S., Monaghan M., Richardson P. J. Regression of left ventricular hypertrophy during treatment with antihypertensive agents. Br J Clin Pharmacol. 1979;7 (Suppl 2):255S–260S. doi: 10.1111/j.1365-2125.1979.tb04698.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hollander W. Role of hypertension in atherosclerosis and cardiovascular disease. Am J Cardiol. 1976 Nov 23;38(6):786–800. doi: 10.1016/0002-9149(76)90357-x. [DOI] [PubMed] [Google Scholar]
- Karlinger J. S., Williams D., Gorwit J., Crawford M. H., O'Rourke R. A. Left ventricular performance in patients with left ventricular hypertrophy caused by systemic arterial hypertension. Br Heart J. 1977 Nov;39(11):1239–1245. doi: 10.1136/hrt.39.11.1239. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Meerson F. Z. The myocardium in hyperfunction, hypertrophy and heart failure. Circ Res. 1969 Jul;25(1 Suppl):1–163. [PubMed] [Google Scholar]
- Sen S., Tarazi R. C., Bumpus F. M. Cardiac hypertrophy and antihypertensive therapy. Cardiovasc Res. 1977 Sep;11(5):427–433. doi: 10.1093/cvr/11.5.427. [DOI] [PubMed] [Google Scholar]
- Symons C., Richardson P. J., Feizi O. Hypertrophic cardiomyopathy and hyperthyroidism: a report of three cases. Thorax. 1974 Nov;29(6):713–719. doi: 10.1136/thx.29.6.713. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Toshima H., Koga Y., Yoshioka H., Akiyoshi T., Kimura N. Echocardiographic classification of hypertensive heart disease. A correlative study with clinical features. Jpn Heart J. 1975 Jul;16(4):377–393. doi: 10.1536/ihj.16.377. [DOI] [PubMed] [Google Scholar]
- de Champlain J., Farley L., Cousineau D., van Ameringen M. R. Circulating catecholamine levels in human and experimental hypertension. Circ Res. 1976 Feb;38(2):109–114. doi: 10.1161/01.res.38.2.109. [DOI] [PubMed] [Google Scholar]